Yuping Cai

Dr. Yuping Cai


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
AVAna Rosen Vollmar
Ana Rosen Vollmar
NRNicholas Rattray
Nicholas Rattray
YCYuping Cai
Yuping Cai
ASAlvaro Santos-Neto
Alvaro Santos-Neto
NDNicole Deziel
Nicole Deziel
Caroline JohnsonCaroline Johnson
Caroline Johnson
Metabolomics studies of the early-life exposome often use maternal urine specimens to investigate critical developmental windows, including the periconceptional period and early pregnancy. During these windows changes in kidney function can impact urine concentration. This makes accounting for differential urinary dilution across samples challenging. Because there is no consensus on the ideal normalization approach for urinary metabolomics data, this study’s objective was to determine the optimal post-analytical normalization approach for untargeted metabolomics analysis from a periconceptional cohort of 45 women. Urine samples consisted of 90 paired pre- and post-implantation samples. After untargeted mass spectrometry-based metabolomics analysis, we systematically compared the performance of three common approaches to adjust for urinary dilution—creatinine adjustment, specific gravity adjustment, and probabilistic quotient normalization (PQN)—using unsupervised principal components analysis, relative standard deviation (RSD) of pooled quality control samples, and orthogonal partial least-squares discriminant analysis (OPLS-DA). Results showed that creatinine adjustment is not a reliable approach to normalize urinary periconceptional metabolomics data. Either specific gravity or PQN are more reliable methods to adjust for urinary concentration, with tighter quality control sample clustering, lower RSD, and better OPLS-DA performance compared to creatinine adjustment. These findings have implications for metabolomics analyses on urine samples taken around the time of conception and in contexts where kidney function may be altered.

8 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YCYuping Cai
Yuping Cai
DKDaniel J. Kim
Daniel J. Kim
TTTakehiro Takahashi
Takehiro Takahashi
DBDavid I Broadhurst
David I Broadhurst
SMShuangge Ma
Shuangge Ma
Caroline JohnsonCaroline Johnson
Caroline Johnson
Coronavirus disease-2019 (COVID-19) has poorer clinical outcomes in males compared to females, and immune responses underlie these sex-related differences in disease trajectory. As immune responses are in part regulated by metabolites, we examined whether the serum metabolome has sex-specificity for immune responses in COVID-19. In males with COVID-19, kynurenic acid (KA) and a high KA to kynurenine (K) ratio was positively correlated with age, inflammatory cytokines, and chemokines and was negatively correlated with T cell responses, revealing that KA production is linked to immune responses in males. Males that clinically deteriorated had a higher KA:K ratio than those that stabilized. In females with COVID-19, this ratio positively correlated with T cell responses and did not correlate with age or clinical severity. KA is known to inhibit glutamate release, and we observed that serum glutamate is lower in patients that deteriorate from COVID-19 compared to those that stabilize, and correlates with immune responses. Analysis of Genotype-Tissue Expression (GTEx) data revealed that expression of kynurenine aminotransferase, which regulates KA production, correlates most strongly with cytokine levels and aryl hydrocarbon receptor activation in older males. This study reveals that KA has a sex-specific link to immune responses and clinical outcomes, in COVID-19 infection.

19 June 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
YCYuping Cai
Yuping Cai
NRNicholas Rattray
Nicholas Rattray
QZQian Zhang
Qian Zhang
VMVarvara Mironova
Varvara Mironova
ASAlvaro Santos-Neto
Alvaro Santos-Neto
Caroline JohnsonCaroline Johnson
Caroline Johnson
The progress in the discovery and validation of metabolite biomarkers for the detection of colorectal cancer (CRC) has been hampered by the lack of reproducibility between study cohorts. The majority of discovery-phase biomarker studies have used patient blood samples to identify disease-related metabolites, but this pre-validation phase is confounded by non-specific disease influences on the metabolome. We therefore propose that metabolite biomarker discovery would have greater success and higher reproducibility for CRC if the discovery phase was conducted in tumor tissues, to find metabolites that have higher specificity to the metabolic consequences of the disease, that are then validated in blood samples. This would thereby eliminate any non-tumor and/or body response effects to the disease. In this study, we performed comprehensive untargeted metabolomics analyses on normal (adjacent) colon and tumor tissues from CRC patients, revealing tumor tissue-specific biomarkers (n = 39/group). We identified 28 highly discriminatory tumor tissue metabolite biomarkers of CRC by orthogonal partial least-squares discriminant analysis (OPLS-DA) and univariate analyses (VIP > 1.5, p < 0.05). A stepwise selection procedure was used to identify nine metabolites that were the most predictive of CRC with areas under the curve (AUCs) of >0.96, using various models. We further identified five biomarkers that were specific to the anatomic location of tumors in the colon (n = 236). The combination of these five metabolites (S-adenosyl-L-homocysteine, formylmethionine, fucose 1-phosphate, lactate, and phenylalanine) demonstrated high differentiative capability for left- and right-sided colon cancers at stage I by internal cross-validation (AUC = 0.804, 95% confidence interval, CI 0.670–0.940). This study thus revealed nine discriminatory biomarkers of CRC that are now poised for external validation in a future independent cohort of samples. We also discovered a discrete metabolic signature to determine the anatomic location of the tumor at the earliest stage, thus potentially providing clinicians a means to identify individuals that could be triaged for additional screening regimens.

2 January 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
BWBenedikt Warth
Benedikt Warth
Amelia PalermoAmelia Palermo
Amelia Palermo
NRNicholas Rattray
Nicholas Rattray
NLNathan V. Lee
Nathan V. Lee
ZZZhou Zhu
Zhou Zhu
Caroline JohnsonCaroline Johnson
Caroline Johnson
The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy.

15 November 2018
Verified
Conference Paper
Open access
Caroline JohnsonCaroline Johnson
Caroline Johnson
NRNicholas Rattray
Nicholas Rattray
YCYuping Cai
Yuping Cai
YZYawei Zhang
Yawei Zhang
SKSajid A Khan
Sajid A Khan
Colon cancer is the second most common cancer to affect women worldwide. While women have a 30-40% lower incidence of colon cancer than men, they have a higher likelihood of cancer presentation on the right-side of the colon. This is of high concern because patients with right-sided colon cancer have poorer clinical outcomes than those with left-sided colon cancers. The reasons for this difference in outcome are not known, however, it has been proposed that female hormones influence colonic metabolism, microbiome and affect tumor growth in this region of the colon. We have initially examined the metabolic differences between 210 colon tumor tissues from men and women with left and right-sided colon cancer using untargeted liquid chromatography mass spectrometry-based metabolomics. We show region- and sex-specific differences in tumor tissue metabolism that may influence tumor aggressiveness and patient outcomes. Video from the Keynote Speaker Dr. Caroline H. Johnson can be found as below:
2